Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. - Wikidata - awgldk - TriplyDB

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q37074226

about

Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses.Novel immunotherapy in metastatic renal cell carcinoma.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art New flow cytometric assays for monitoring cell-mediated cytotoxicity Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.TroVax in colorectal cancer An update on TroVax for the treatment of progressive castration-resistant prostate cancer A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)Viral vector-based therapeutic cancer vaccines Interleukin-2 administration after modified radical mastectomy in breast cancer therapy increases peripheral regulatory T cells.The immunologic aspects of poxvirus oncolytic therapy CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model Poxviral vectors for cancer immunotherapy A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Enhancing poxvirus vectors vaccine immunogenicity.Update on vaccine development for renal cell cancer.A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.Imaging the immune response to monitor tumor immunotherapy.Use of attenuated paramyxoviruses for cancer therapy.Therapeutic vaccines in renal cell carcinoma.TroVax(®) vaccine therapy for renal cell carcinoma.Cancer vaccines: identification of biomarkers predictive of clinical efficacy Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Fighting Cancer with Mathematics and Viruses.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis.Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.Targeting targeted therapies.Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

P2860

Q27016032-161ECEBF-4D0B-4AFD-BD85-B8B7D370EC8D Q28740522-A1910B36-338C-437B-8723-75C5D1C40105 Q33606166-2914EE35-B74F-4C47-B636-77EA4B1E797B Q33863074-1C044F30-754F-4CDA-8DB7-A1DD07DA7BB3 Q33907628-4FA18ADF-57B1-4974-A5D6-24B0743FBC8D Q34027777-A92054DB-D242-4558-96F9-8C38C917A501 Q34260594-DE3760F8-B4B1-42AF-91C5-AE160AD414FC Q34452474-41A2B9C3-5D64-40EE-8218-D98E2321CAF2 Q35050205-9AB50255-F00F-4402-88D0-72BBB0C3197C Q35053133-AC949CEF-12F0-4893-9D85-D297CD16CAC5 Q35515080-A02C8486-F74F-42F8-94C7-2CF874B149F6 Q35870925-E7B89970-EAF1-4B00-86B0-F533AFEB6297 Q36115128-60BDCC56-976F-4AD1-B5ED-B39A7F2EB09F Q36177214-5FC135C1-16EE-41A3-8C08-D057E430B802 Q36350388-133737CF-7F44-4B2C-B27F-E9DE7C5254C4 Q36391900-D93A95CF-E5D1-4642-859D-E28E90B4CFB4 Q36978452-120E4FB1-A199-40DA-B1CF-F42F47A722F6 Q36989720-4B4E0063-B8F8-464D-AA9D-7F2C0B7398B5 Q37004283-848611E9-DBA0-4A55-9A6F-20588E705195 Q37608319-8DFD5118-F617-41A6-B7C7-F8A0AA2D3987 Q37810599-AEB4D11B-C144-4E4E-8389-7291EF33B320 Q37922585-BEAF8F39-8D22-4D5C-A955-A18142147C73 Q37965748-F7EA9A85-E6EA-48C2-B4EA-45A557954355 Q38096820-F50A6F50-3B47-4302-A198-C23E17ECB52A Q38110934-720BB9E7-25B7-4BF9-AF9B-25C785FB40B3 Q38123176-607DA7B8-D936-491C-BF86-563EA4FDA9AE Q38248440-0DD55EDF-0D95-4D40-B7C7-9175FF8169ED Q38612646-2DDCA83F-FDB9-4CE6-99D8-58BDA77360C8 Q38984929-2E2EE6AA-FFB6-41B8-B982-238027320E54 Q39774023-203CA58F-90FA-43F0-A032-5053CE424D72 Q42113023-7718627C-9E32-49AF-BC9B-B7516AE98380 Q42282117-833B5ED0-B7DE-478C-A113-63CFF9E1036D Q42797009-4E6DA0AA-63EC-4F00-ADE3-0AF5EE0D3CD6 Q47630188-69E045A4-E886-4923-A8A4-D018716EA55D Q50034069-B52402A2-B36E-4C40-9739-10B1218A9811 Q56965832-21279DBE-7829-4C3A-8EAE-9812F461E993

P2860

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q37074226

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II trial of Modified Vac ...... tastatic renal cell carcinoma.

@en

Phase II trial of Modified Vaccinia Ankara

@nl

type

label

Phase II trial of Modified Vac ...... tastatic renal cell carcinoma.

@en

Phase II trial of Modified Vaccinia Ankara

@nl

prefLabel

Phase II trial of Modified Vac ...... tastatic renal cell carcinoma.

@en

Phase II trial of Modified Vaccinia Ankara

@nl

P1433

Q37074226-ED534A0F-5ED3-4F0D-A510-AC7B66B87333

P1476

Q37074226-8128F18D-077E-4530-ACFE-BD6C82FBA6B3

P2093

Q37074226-07792BC7-F2DB-4553-9B5D-76B712824459

Q37074226-4E52904B-9F00-4987-B2BF-E0CC5D256A3E

Q37074226-6D634F60-1B87-4C2D-824A-363CC1766300

Q37074226-A00FE88F-7366-4162-9C98-C373D950DC19

Q37074226-A3EDAD19-3A5C-4EF3-88E3-8396BB5CB7F6

Q37074226-A79212A8-7476-401D-8C10-F048E389D798

Q37074226-B120F879-B880-4244-A351-C7A59489B15C

Q37074226-BBCC8F1B-247B-4768-A938-360E2549ADB4

Q37074226-CF6C88B3-F130-4724-8072-1B43E6EEF922

Q37074226-E30CB302-C492-4BB7-AB2C-7A1B0B43D432

P2860

Q37074226-09B84D2C-029A-4E42-9374-7DA087463521

Q37074226-0E17DB68-FB45-4DB9-975A-A0C464A2C66A

Q37074226-0F8EC4E4-E12B-4A51-B049-F43427B3B2FC

Q37074226-2F555EF7-8859-4652-BC05-9E40ADBAB32B

Q37074226-40720761-63C6-4405-966F-67B463BED1AE

Q37074226-47E97C6A-1CD8-4563-A40F-A2133C7B0471

Q37074226-56DA493B-4B15-4281-9C43-746A236D1F8A

Q37074226-6D251E99-15B6-4F8B-8FFA-45F7F3685707

Q37074226-73E00DAB-24DC-4B1D-B0FF-B8C5CBAC253B

Q37074226-84D36B26-199B-4173-8EA9-89B8D7744C97

P2888

Q37074226-D6E71EE6-4A33-4A81-A5C8-1766BA162C84

P304

Q37074226-F1457895-17F8-451D-B983-883A85EE36C5

P31

Q37074226-72B050D9-9878-44F3-8DA4-069A473E80DB

P356

Q37074226-3B7A5E0C-259D-406A-8758-AD931E31CD37

P478

Q37074226-1DAA0DE0-D60E-44D4-82F3-54312A675670

P577

Q37074226-046081B5-2EA4-45D6-AD20-B00E568E8851

P5875

Q37074226-D1A36A4C-C151-473E-98B9-B28E8DE29A8C

P6179

Q37074226-2A5649F7-79A0-493A-8895-CDDBE966C1B7

P698

Q37074226-76F74AB7-5763-42AF-A874-7D855EDABAFD

P921

Q37074226-19191320-d192-4537-aacf-a4b9625b27fe

Q37074226-DE081749-8841-447B-BF21-71E706A427C5

P932

Q37074226-07CB0E4B-54C4-45E5-9101-BACEC2CC155C

P356

P1433

Journal of Translational Medicine

P1476

Phase II trial of Modified Vac ...... tastatic renal cell carcinoma.

@en

P2093

Bret Taback

http://www.w3.org/2001/XMLSchema#string

Dae Won Kim

http://www.w3.org/2001/XMLSchema#string

Dorota Moroziewicz

http://www.w3.org/2001/XMLSchema#string

Gail DeRaffele

http://www.w3.org/2001/XMLSchema#string

Howard L Kaufman

http://www.w3.org/2001/XMLSchema#string

Josephine Mitcham

http://www.w3.org/2001/XMLSchema#string

Miles W Carroll

http://www.w3.org/2001/XMLSchema#string

Richard Harrop

http://www.w3.org/2001/XMLSchema#string

Seunghee Kim-Schulze

http://www.w3.org/2001/XMLSchema#string

Stuart Naylor

http://www.w3.org/2001/XMLSchema#string

P2860

Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

The expression of 5T4 antigen in colorectal and gastric carcinoma

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

Interleukin-2: clinical applications.

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

P2888

P304

2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-7-2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23763335

http://www.w3.org/2001/XMLSchema#string

P6179

1047469425

http://www.w3.org/2001/XMLSchema#string

P698

19128501

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2631474

http://www.w3.org/2001/XMLSchema#string